Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stopping anti-TNF treatment in Crohn's and Colitis patients in remission
2024-513299-17-00Phase 4Authorised
- Sponsor
- Region Skåne
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of infliximab and adalimumab in autoimmune colitis and Crohn's disease (2 arms), sponsored by Region Skåne. Planned start Sep 2024; status: authorised.
02
Drugs
infliximabadalimumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2024-513299-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513299-17-00.